0000950170-24-075568.txt : 20240620 0000950170-24-075568.hdr.sgml : 20240620 20240620160506 ACCESSION NUMBER: 0000950170-24-075568 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240611 FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Buell Jennifer CENTRAL INDEX KEY: 0001711184 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 241056175 BUSINESS ADDRESS: BUSINESS PHONE: 781-674-4400 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 3 1 ownership.xml 3 X0206 3 2024-06-11 0 0001098972 AGENUS INC AGEN 0001711184 Buell Jennifer 3 FORBES ROAD LEXINGTON MA 02421 true true false false Chairman Executive Council Common Stock 13670 D Stock Option, right to buy 100.80 2015-05-12 2025-02-12 Common Stock 1225 D Stock Option, right to buy 100.80 2015-02-12 2025-02-12 Common Stock 525 D Stock Option, right to buy 83.2 2017-03-31 2026-03-31 Common Stock 5000 D Stock Option, right to buy 75.40 2018-03-31 2027-03-31 Common Stock 6250 D Stock Option, right to buy 41.40 2018-11-07 2028-11-07 Common Stock 6500 D Stock Option, right to buy 47.60 2019-06-19 2029-06-19 Common Stock 15000 D Stock Option, right to buy 82.40 2019-12-24 2029-12-24 Common Stock 24999 D Stock Option, right to buy 72.20 2020-06-15 2030-06-15 Common Stock 500 D Stock Option, right to buy 74.00 2020-12-17 2030-12-17 Common Stock 44999 D Stock Option, right to buy 63.60 2021-06-16 2031-01-01 Common Stock 45000 D Stock Option, right to buy 64.40 2022-01-02 2032-01-02 Common Stock 7500 D Stock Option, right to buy 47.40 2023-01-09 2033-01-09 Common Stock 37500 D Stock Option, right to buy 11.80 2024-06-11 2034-01-17 Common Stock 37500 D Options awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan (as amended) and vests over four years with one third vesting on the 2-year anniversary of the grant date (January 1, 2021) and the balance in equal quarterly installments thereafter. Options awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan (as amended) and vests over three years with one third vesting on the one year anniversary of the grant date (January 1, 2022) and the balance in equal quarterly installments thereafter. Options awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan (as amended) and vests over three years with one third vesting on the one year anniversary of the grant date (January 9, 2023) and the balance in equal quarterly installments thereafter. Options were granted on January 17, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 750,000 Stock Options with an exercise price of $0.59.. Christine M. Klaskin, by Power of Attorney 2024-06-18